経肺薬剤送達装置のグローバル市場予測(~2027年)

◆英語タイトル:Pulmonary Drug Delivery Devices Market Research Report by Product Type, Application, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが発行した調査報告書(360iR22DC028)◆商品コード:360iR22DC028
◆発行会社(リサーチ会社):360iResearch
◆発行日:2022年10月
◆ページ数:222
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,949 ⇒換算¥732,452見積依頼/購入/質問フォーム
Enterprise LicenseUSD9,949 ⇒換算¥1,472,452見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

360iResearch社発行の当調査資料では、2021年に448.2億ドルであった世界の経肺薬剤送達装置市場規模が2022年に473.4億ドルに達し、2028年には629.1億ドルまで年平均5.81%で成長すると予測しています。当書は、経肺薬剤送達装置の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品タイプ別(乾燥粉末吸入器、定量噴霧器、ネブライザー)分析、用途別(気管支喘息、COPD、嚢胞性線維症)分析、流通チャネル別(病院薬局、調剤薬局)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況などの内容をまとめています。なお、当書には、Aerogen、AstraZeneca Plc、Boehringer Ingelheim Gmbh、Briggs Healthcare, Inc.、Celares GmbH、Cipla Inc、GF Health Products, Inc.、Gilbert Technologies、GlaxoSmithKline Plc、Jabil Inc、Koninklijke Philips N.V.などの企業情報が含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト

・世界の経肺薬剤送達装置市場規模:製品タイプ別
- 乾燥粉末吸入器の市場規模
- 定量噴霧器の市場規模
- ネブライザーの市場規模

・世界の経肺薬剤送達装置市場規模:用途別
- 気管支喘息用経肺薬剤送達システムの市場規模
- COPD用経肺薬剤送達システムの市場規模
- 嚢胞性線維症用経肺薬剤送達システムの市場規模

・世界の経肺薬剤送達装置市場規模:流通チャネル別
- 病院薬局の市場規模
- 調剤薬局の市場規模

・世界の経肺薬剤送達装置市場規模:地域別
- 南北アメリカの経肺薬剤送達装置市場規模
アメリカの経肺薬剤送達装置市場規模
カナダの経肺薬剤送達装置市場規模
ブラジルの経肺薬剤送達装置市場規模
...
- アジア太平洋の経肺薬剤送達装置市場規模
日本の経肺薬剤送達装置市場規模
中国の経肺薬剤送達装置市場規模
インドの経肺薬剤送達装置市場規模
韓国の経肺薬剤送達装置市場規模
台湾の経肺薬剤送達装置市場規模
...
- ヨーロッパ/中東/アフリカの経肺薬剤送達装置市場規模
イギリスの経肺薬剤送達装置市場規模
ドイツの経肺薬剤送達装置市場規模
インドの経肺薬剤送達装置市場規模
フランスの経肺薬剤送達装置市場規模
ロシアの経肺薬剤送達装置市場規模
...
- その他地域の経肺薬剤送達装置市場規模

・競争状況
・企業情報

The Global Pulmonary Drug Delivery Devices Market size was estimated at USD 44.82 billion in 2021 and expected to reach USD 47.34 billion in 2022, and is projected to grow at a CAGR 5.81% to reach USD 62.91 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Pulmonary Drug Delivery Devices to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product Type, the market was studied across Dry Powder Inhaler, Metered Dose Inhaler, and Nebulizer.

Based on Application, the market was studied across Asthma, COPD, and Cystic Fibrosis.

Based on Distribution Channel, the market was studied across Hospital Pharmacies and Retail Pharmacy Stores.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Pulmonary Drug Delivery Devices market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Drug Delivery Devices Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Drug Delivery Devices Market, including Aerogen, AstraZeneca Plc, Boehringer Ingelheim Gmbh, Briggs Healthcare, Inc., Celares GmbH, Cipla Inc, GF Health Products, Inc., Gilbert Technologies, GlaxoSmithKline Plc, Jabil Inc, Koninklijke Philips N.V., MannKind Corporation, Merck & Co., Inc., Mylan N.V., Novartis AG, Omron Corporation, Sunovion Pharmaceuticals Inc., and The 3M Company.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Pulmonary Drug Delivery Devices Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Drug Delivery Devices Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Drug Delivery Devices Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Drug Delivery Devices Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Drug Delivery Devices Market?
6. What is the market share of the leading vendors in the Global Pulmonary Drug Delivery Devices Market?
7. What modes and strategic moves are considered suitable for entering the Global Pulmonary Drug Delivery Devices Market?

❖ レポートの目次 ❖

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of chronic respiratory diseases globally
5.1.1.2. Surge in use of development of digital or smart inhalers
5.1.1.3. Increasing shift toward pulmonary drug delivery devices as alternate route
5.1.2. Restraints
5.1.2.1. Issues concerned with price and regulations
5.1.3. Opportunities
5.1.3.1. Emerging technological advancements in pulmonary devices
5.1.3.2. Increasing healthcare expenditure on therapeutic devices
5.1.4. Challenges
5.1.4.1. Difficulty in maintenance due to deposition of aerosolized particles
5.2. Cumulative Impact of COVID-19

6. Pulmonary Drug Delivery Devices Market, by Product Type
6.1. Introduction
6.2. Dry Powder Inhaler
6.3. Metered Dose Inhaler
6.4. Nebulizer

7. Pulmonary Drug Delivery Devices Market, by Application
7.1. Introduction
7.2. Asthma
7.3. COPD
7.4. Cystic Fibrosis

8. Pulmonary Drug Delivery Devices Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Retail Pharmacy Stores

9. Americas Pulmonary Drug Delivery Devices Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Pulmonary Drug Delivery Devices Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Pulmonary Drug Delivery Devices Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Aerogen
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. AstraZeneca Plc
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Boehringer Ingelheim Gmbh
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Briggs Healthcare, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Celares GmbH
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Cipla Inc
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. GF Health Products, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Gilbert Technologies
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. GlaxoSmithKline Plc
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Jabil Inc
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Koninklijke Philips N.V.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. MannKind Corporation
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Merck & Co., Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Mylan N.V.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Novartis AG
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Omron Corporation
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Sunovion Pharmaceuticals Inc.
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. The 3M Company
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 経肺薬剤送達装置のグローバル市場予測(~2027年)(Pulmonary Drug Delivery Devices Market Research Report by Product Type, Application, Distribution Channel, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆